Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1119]

Genomic profiling of muscle invasive bladder cancer to predict response to...

Dr David Miyamoto - Massachusetts General Hospital, Boston, USA

Genomic profiling of muscle invasive bladder cancer to predict response to bladder-sparing trimodality therapy ( Dr David Miyamoto - Massachusetts General Hospital, Boston, USA )

Tumour fraction in circulating free DNA as a biomarker of disease dynamics in...

Dr Atish Choudhury - Dana-Farber Cancer Institute, Boston, USA

$Tumour fraction in circulating free DNA as a biomarker of disease dynamics in metastatic prostate cancer ( Dr Atish Choudhury - Dana-Farber Cancer Institute, Boston, USA )$

Crizotinib for advanced papillary renal cell carcinoma with MET mutations or...

Prof Patrick Schöffski - The Katholieke Universiteit Leuven, Leuven, Belgium

Crizotinib for advanced papillary renal cell carcinoma with MET mutations or amplification ( Prof Patrick Schöffski - The Katholieke Universiteit Leuven, Leuven, Belgium )

Serum miRNA to predict post-chemotherapy viable disease in testicular non...

Dr Ricardo Leão - University of Toronto, Toronto, Canada

Serum miRNA to predict post-chemotherapy viable disease in testicular non-seminomatous germ cell tumour patients ( Dr Ricardo Leão - University of Toronto, Toronto, Canada )

Radium-223 for bone predominant metastatic castration resistant prostate cancer

Dr Andrew Armstrong - Duke University School of Medicine, Durham, USA

Radium-223 for bone predominant metastatic castration resistant prostate cancer ( Dr Andrew Armstrong - Duke University School of Medicine, Durham, USA )

FALCON: Impact of 18F-fluciclovine PET/CT on management of biochemically...

Dr Eugene Teoh - University of Oxford, Oxford, UK

FALCON: Impact of 18F-fluciclovine PET/CT on management of biochemically recurrent prostate cancer ( Dr Eugene Teoh - University of Oxford, Oxford, UK )

PROSPER RCC study of perioperative nivolumab for renal cell carcinoma - future...

Dr Lauren Harshman - Dana-Farber Cancer Institute, Boston, USA

PROSPER RCC study of perioperative nivolumab for renal cell carcinoma - future trial ( Dr Lauren Harshman - Dana-Farber Cancer Institute, Boston, USA )

POUT: Phase III randomised trial of perioperative chemotherapy vs surveillance...

Dr Alison Birtle - Lancashire Teaching Hospitals NHS Foundation Trust...

POUT: Phase III randomised trial of perioperative chemotherapy vs surveillance in upper tract urothelial cancer ( Dr Alison Birtle - Lancashire Teaching Hospitals NHS Foundation Trust, Lancashire, UK )

Updates on non-metastatic castration-resistant prostate cancer

Prof Kurt Miller, Prof Silke Gillessen, Prof Heather Payne and Dr Eric Small

Updates on non-metastatic castration-resistant prostate cancer ( Prof Kurt Miller, Prof Silke Gillessen, Prof Heather Payne and Dr Eric Small )

Latest in adjuvant therapy for renal cell carcinoma

Dr Naomi Haas - University of Pennsylvania, Philadelphia, USA

Latest in adjuvant therapy for renal cell carcinoma ( Dr Naomi Haas - University of Pennsylvania, Philadelphia, USA )

Updates in metastatic prostate cancer

Prof Heather Payne, Dr Neal Shore, Dr Eleni Efstathiou, Prof Nicolas Mottet

Updates in metastatic prostate cancer ( Prof Heather Payne, Dr Neal Shore, Dr Eleni Efstathiou, Prof Nicolas Mottet )

Hypoxia related mRNA biomarker to predict biochemical failure and metastasis...

Dr Ananya Choudhury - The Christie NHS Foundation Trust, Manchester, UK

Hypoxia related mRNA biomarker to predict biochemical failure and metastasis for prostate cancer ( Dr Ananya Choudhury - The Christie NHS Foundation Trust, Manchester, UK )

More from ecancer